Retatrutide: the triple agonist that could rewrite the GLP-1 era

What retatrutide is

Retatrutide (development code LY3437943) is a once-weekly synthetic peptide developed by Eli Lilly that activates three receptors in a single molecule: the GLP-1 (glucagon-like peptide-1) receptor, the GIP (glucose-dependent insulinotropic polypeptide) receptor, and the glucagon receptor. It sits one engineering generation ahead of tirzepatide, which activates only GLP-1 and GIP, and two generations ahead of semaglutide, which is a selective GLP-1 receptor agonist [Coskun 2022].

Lilly's pipeline framing is unsubtle. Semaglutide was the first commercial incretin to clear the −10% weight threshold reliably. Tirzepatide cleared −20%. Retatrutide is being positioned to clear −25%, and the phase-2 readout discussed below is what gives that positioning trial-level support rather than press-release support [Jastreboff 2023].

Two notes worth holding before the mechanism section. First, every number in this article comes from a phase-2 trial. Phase-2 readouts in incretin drugs have historically held up reasonably well into phase 3, but they have also overstated effect size for safety-pruned subgroups and understated side-effect frequency. Second, retatrutide is not approved by any major regulator at the time of writing. Anyone receiving it outside a phase-3 site is receiving a compounded or unregulated product, which is a category we are not endorsing.

Mechanism: why adding the glucagon receptor matters

The intuitive read of glucagon is that it raises blood sugar — which it does, in the fasted state, by signaling hepatic glucose output. That framing makes a glucagon agonist sound like the opposite of what you want in a metabolic drug. The real story is more interesting. Glucagon receptor signaling, in the context of co-activated GLP-1 signaling that keeps glucose in range, drives an increase in resting energy expenditure and a meaningful reduction in hepatic fat [Boland 2020].

In healthy human physiology, the body burns fuel through a combination of basal metabolic rate, the thermic effect of food, and activity. Most weight-loss interventions — diet, GLP-1 monotherapy, even bariatric surgery — reduce intake without raising expenditure, and the body adapts by reducing expenditure further to defend mass. The promise of glucagon receptor agonism, paired with GLP-1, is that it pushes the energy expenditure side of the equation in the opposite direction, partially offsetting the adaptive thermogenic decline that has frustrated every previous era of weight-loss pharmacology [Knerr 2022].

Glucagon agonism alone would raise blood glucose. Glucagon agonism layered onto GLP-1 and GIP agonism shifts net signaling toward higher energy expenditure, lower hepatic fat, and tighter glycemic control — a combination no previous class achieves.

What the three receptors do, briefly

• GLP-1 receptor — glucose-dependent insulin secretion, delayed gastric emptying, central satiety signaling, glucagon suppression in the fed state.
• GIP receptor — augments insulin secretion further, modulates adipocyte handling of nutrients, and may attenuate the nausea ceiling that limits GLP-1 monotherapy dosing.
• Glucagon receptor — increases resting energy expenditure, mobilizes hepatic lipid stores, raises lipolysis. Net glycemic effect is offset by the co-activated GLP-1 and GIP pathways.

The mechanistic case for retatrutide is that this composite receptor map more closely mimics endogenous post-prandial signaling than any single or dual agonist can. Whether that mechanistic case translates into durable phase-3 outcomes — including cardiovascular (CV) and hepatic endpoints — is the question the TRIUMPH program is built to answer.

The phase-2 readout

The pivotal phase-2 obesity trial, published by Jastreboff and colleagues in the New England Journal of Medicine in 2023, randomized 338 adults with obesity or overweight plus a comorbidity to escalating doses of retatrutide or placebo for 48 weeks. The 12 mg arm reported a mean weight change of −24.2% (versus −2.1% on placebo) [Jastreboff 2023]. The 8 mg arm reported −22.8%. Both figures are unprecedented for any incretin-class compound at the equivalent timepoint.

A companion phase-2 readout in type 2 diabetes, published by Rosenstock and colleagues in The Lancet in 2023, reported HbA1c reductions approaching −2.0% at the higher retatrutide doses with concurrent weight loss of roughly −16.9% at 36 weeks [Rosenstock 2023]. As with every incretin agent in this class so far, diabetes blunts the weight response, but the glycemic response is robust.

Two phase-2 features deserve flagging. First, the weight-loss curve had not plateaued at 48 weeks, which suggests the true ceiling may be higher than −24.2% with longer exposure. Second, dose-dependent increases in heart rate (roughly 6–11 bpm versus placebo at the higher arms) were reported, along with the expected gastrointestinal tolerability profile. The heart rate signal is mechanistically consistent with glucagon receptor agonism and is the single most important safety signal phase-3 will need to characterize.

How it compares — semaglutide, tirzepatide

The temptation is to put retatrutide's −24.2% next to tirzepatide's −20.9% and semaglutide's −14.9% and declare a winner. We are not going to do that, because the comparisons are cross-trial — different populations, different durations, different placebo arms, different run-in rules. The numbers below are the cleanest available anchors for each agent in obese, non-diabetic populations:

• Semaglutide 2.4 mg — STEP 1, 68 weeks, mean weight change −14.9% [Wilding 2021].
• Tirzepatide 15 mg — SURMOUNT-1, 72 weeks, mean weight change −20.9% (some analyses report −22.5% in completers) [Jastreboff 2022].
• Retatrutide 12 mg — phase 2, 48 weeks, mean weight change −24.2% [Jastreboff 2023].

Notice the durations. Retatrutide hit a larger number in 20 fewer weeks than the SURMOUNT-1 readout for tirzepatide. The longer phase-3 follow-up will either confirm the trajectory or reveal a plateau and reversion pattern that phase-2 was too short to see. Until then, the responsible framing is that retatrutide is plausibly the most efficacious weight-loss agent ever tested — and the phase-3 ceiling is genuinely unknown.

Phase-3 outlook: the TRIUMPH program

Lilly's phase-3 program for retatrutide in obesity and obesity-adjacent indications is registered under the TRIUMPH umbrella at clinicaltrials.gov. The publicly disclosed studies include:

• TRIUMPH-1 — retatrutide in adults with obesity or overweight, no diabetes, the registrational efficacy and safety study analogous to STEP 1 / SURMOUNT-1.
• TRIUMPH-2 — retatrutide in adults with type 2 diabetes (T2D), parallel to SURMOUNT-2.
• TRIUMPH-3 — retatrutide in adults with obesity and established cardiovascular disease, a higher-comorbidity cohort.
• TRIUMPH-4 — retatrutide in adults with obesity and knee osteoarthritis, a quality-of-life and function endpoint study.
• TRIUMPH-OUTCOMES — the dedicated cardiovascular outcomes trial, structured to deliver hard endpoints comparable to SELECT for semaglutide.

The first readouts from TRIUMPH-1 and TRIUMPH-2 are expected to deliver the registrational obesity and T2D data. TRIUMPH-OUTCOMES is the long-tail study that, if positive, would transform retatrutide from a weight-loss compound into a cardiometabolic compound the way SELECT did for semaglutide. Anyone modeling retatrutide's commercial or clinical trajectory should weight TRIUMPH-OUTCOMES heavily.

Open questions

The phase-2 readout was a strong signal, not a finished story. Four questions matter for whether retatrutide displaces tirzepatide as the standard of care.

1. Cardiovascular safety. The dose-dependent heart rate elevation seen in phase 2 is the central pharmacovigilance question. GLP-1 monotherapy also raises heart rate modestly without translating into adverse CV outcomes, and SELECT in fact showed benefit. Whether glucagon receptor agonism preserves that pattern or reverses it is what TRIUMPH-OUTCOMES is designed to settle. Until it reads out, the heart rate signal is the grey area.
2. Long-term tolerability. Phase-2 reported the expected gastrointestinal side-effect profile, with discontinuation rates broadly consistent with tirzepatide. Two-year and five-year data, including discontinuation patterns once novelty fades, are not yet available.
3. Hepatic fat reduction. Glucagon receptor agonism is mechanistically promising for metabolic dysfunction-associated steatohepatitis (MASH), the modern name for what used to be called NASH. Phase-2 imaging substudies were encouraging. Phase-3 MASH-specific endpoints, if they materialize, would open a second indication. This is upside, not core thesis.
4. Lean mass. The lean-mass critique that follows every incretin agent has not been resolved by phase-2 imaging substudies, which were small. If retatrutide drives larger absolute weight loss than tirzepatide, the absolute lean-mass loss is likely larger too, even if the percentage composition is similar. Protein intake and resistance training during titration remain the intervention with the strongest evidence base for preserving fat-free mass during pharmacologic weight loss.

The competitive landscape

Retatrutide is not advancing through phase 3 unopposed. The industry pipeline behind it is the densest the metabolic space has ever seen, and three competitor programs matter for how the next five years play out.

CagriSema (Novo Nordisk) pairs the amylin analog cagrilintide with semaglutide in a single injection. The REDEFINE-1 readout reported approximately −22.7% weight loss — clinically meaningful but below Novo's pre-trial guidance, which the equity market punished. CagriSema is the incumbent's response to tirzepatide, not a leap past it.

Orforglipron (Eli Lilly) is a non-peptide, orally bioavailable GLP-1 receptor agonist. Its weight-loss numbers are smaller than the injectable triple agonists, but the format is the disruption. An oral GLP-1 manufactured at small-molecule scale is a fundamentally different access and cost story than a peptide that requires cold-chain logistics and weekly self-injection. For most of the patient pool, incremental weight-loss percentage matters less than whether the drug is affordable, available, and tolerable long-term [Wharton 2023].

Survodutide (Boehringer Ingelheim / Zealand) is a dual GLP-1 / glucagon agonist, structurally simpler than retatrutide but operating on overlapping mechanism. Phase-2 weight loss landed in the high teens. The MASH program around survodutide is arguably more interesting than the obesity program, given the glucagon component's hepatic effects.

Our editorial position has not changed. Phase-2 data is a signal, not a verdict. Retatrutide is the most promising weight-loss compound currently in development, and the phase-3 readouts will determine whether that promise survives contact with longer follow-up, harder endpoints, and a broader patient population. Until those readouts land, the responsible posture is interested, not converted.